Company Overview

Alterity Therapeutics Limited is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases associated with pathological protein aggregation and metal dysregulation. The company operates within the biopharmaceutical and central nervous system (CNS) therapeutics industries, with research centered on diseases such as Multiple System Atrophy (MSA), Parkinson’s disease, and related neurodegenerative disorders. Alterity’s primary value driver is its pipeline of small-molecule therapeutics designed to inhibit protein aggregation and restore normal metal homeostasis in the brain. The company’s lead candidate, ATH434, has been the central focus of its clinical development efforts.

Alterity originated as Prana Biotechnology Limited before rebranding to Alterity Therapeutics in 2019 to reflect its strategic focus on neurodegenerative disease therapeutics. The company has historically emphasized proprietary drug discovery platforms targeting neurodegeneration mechanisms linked to alpha-synuclein accumulation and oxidative stress. Its positioning is differentiated by its focus on disease-modifying therapies rather than symptomatic treatments, particularly in rare and underserved neurological disorders where approved treatment options remain limited.

Business Operations

Alterity generates value primarily through the advancement of its therapeutic development pipeline, intellectual property portfolio, and clinical-stage research programs. The company’s operations are centered on drug discovery, preclinical development, and clinical trials, with expenditures primarily directed toward research and development activities. Its principal operating assets include proprietary compounds, patent portfolios, and clinical data associated with neurodegenerative disease treatment candidates. The company’s most prominent program, ATH434, has been evaluated in clinical studies targeting Multiple System Atrophy and related synucleinopathies.

Operations are conducted primarily through research collaborations, outsourced manufacturing arrangements, and clinical trial partnerships across multiple jurisdictions. Alterity maintains relationships with academic institutions, contract research organizations, and specialized neuroscience investigators to support development activities. The company operates internationally through a combination of Australian corporate infrastructure and U.S.-focused capital market presence, including trading on the OTC market under the symbol PRNAF and ADR-related investor access. Public disclosures in SEC filings and Australian Securities Exchange announcements indicate that revenue generation remains limited, with funding historically sourced through equity offerings, strategic financing activities, and investor capital.

Strategic Position & Investments

Alterity’s strategic direction centers on advancing disease-modifying therapies for neurodegenerative disorders with significant unmet medical need. The company has prioritized the clinical development of ATH434, particularly in Multiple System Atrophy, where regulatory pathways for orphan and fast-track-oriented development may provide strategic advantages. Its broader research strategy has also included exploration of therapies targeting alpha-synuclein biology, iron accumulation, and neuroprotective mechanisms relevant to Parkinsonian disorders and dementia-related diseases.

The company has invested substantially in clinical research infrastructure, biomarker development, and intellectual property protection supporting its neurodegenerative disease platform. Alterity has historically leveraged scientific collaborations and licensing arrangements tied to metal-protein attenuation technologies originally developed through academic and research partnerships. Data regarding large-scale acquisitions or diversified subsidiary holdings is inconclusive based on available public sources, as the company remains primarily focused on internally developed CNS therapeutic programs rather than broad portfolio expansion.

Geographic Footprint

Alterity Therapeutics is headquartered in Melbourne, Australia, with operational and investor engagement activities extending into the United States and other international clinical research markets. The company maintains a cross-border structure that supports Australian research operations alongside access to U.S. capital markets and biotechnology investors. Clinical development activities have involved research sites and investigators across Australia, North America, and select international regions associated with neurological disease trials.

Its market presence is concentrated in regions with advanced biotechnology ecosystems and neurological research infrastructure. While the company does not maintain a broad commercial footprint due to its clinical-stage status, it participates in global scientific conferences, international regulatory processes, and multinational clinical research collaborations. Publicly available disclosures indicate that Alterity’s operational influence is primarily research-driven rather than commercial or manufacturing-based.

Leadership & Governance

Alterity Therapeutics is led by an executive team with backgrounds in biotechnology commercialization, neuroscience research, and pharmaceutical development. The company’s strategic vision emphasizes advancing innovative therapeutics capable of slowing or modifying neurodegenerative disease progression through targeted scientific approaches and rigorous clinical validation. Governance is supported through a board structure consistent with publicly traded biotechnology companies listed in Australia and accessible to U.S. investors through OTC trading mechanisms.

Key executives and leadership figures include:

• David Stamler – Chief Executive Officer
• David Stamler – Executive Director
• Karl Herrup – Chief Scientific Officer
• Kevin Craig – Chief Medical Officer
• Adrienne L. Graves – Independent Non-Executive Chair
• James Garner – Non-Executive Director
• Geoffrey Kempler – Non-Executive Director

Leadership information, company structure, and operational disclosures are reflected in publicly available SEC filings, Australian Securities Exchange announcements, annual reports, and investor presentations. Where executive role changes or board appointments differ across reporting periods, the most recently available public disclosures were prioritized.